Pharma plant explosion in India kills 3 workers

An explosion at a biotech plant near New Delhi in India has left workers dead. (Pixabay)

For the second time in eight weeks, there have been deaths tied to an explosion at a pharmaceutical manufacturing facility, this time in India.

Three workers were killed instantly when the boiler they were working on at Pusilin Biotechnology Private exploded, the Xinhua News Agency reported. The plant is in Haryana, near New Delhi.

According to the Chinese Embassy in India, two of the engineers were Chinese and one was Indian, the news agency reported.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

It was in April that 10 workers died of smoke inhalation caused by an explosion and fire at a Chinese drug manufacturing plant. The explosion at the Qilu Tianhe Huishi Pharmaceutical Co. facility in eastern Shandong province was caused by sparks as workers welded a pipe under the plant.

RELATED: 10 killed in explosion at Chinese pharma plant

That explosion, in turn, followed one in March at a chemical plant in eastern Jiangsu province that killed 78 and injured hundreds. Those blasts again raised questions about the safety conditions at pharma plants in China.

In 2015, a massive fire and explosions in the Tianjin industrial port in China killed 160 people and left a massive area of destruction. GlaxoSmithKline had to stop production at a plant in the area following the blasts. No GSK workers were hurt by the nearby event, but the facility was damaged.

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.